Redbiotec Collaborates with GE Healthcare Life Sciences on Vaccine Development and Manufacturing - - BioPharm International

ADVERTISEMENT

Redbiotec Collaborates with GE Healthcare Life Sciences on Vaccine Development and Manufacturing


Redbiotec, a Swiss biopharmaceutical company specializing in vaccine development, is collaborating with GE Healthcare Life Sciences to develop and produce vaccines against cytomegalovirus (CMV), a common virus in the herpes family of viruses. Using GE Healthcare's single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a novel process for the production, clarification, and concentration of CMV-like particles.

Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. This technology is used to support the company’s mission to discover and develop vaccines against the highly prevalent influenza and herpes viruses.

Source: Redbiotec

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here